NCT01381484

Argireline in Treatment of Periorbital Wrinkles

Efficacy and Safety of Topical Argireline in the Treatment of Periorbital Wrinkles

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 70 (actual)
• Sponsor: Mahidol University · Academic / Other
• Sex: Female
• Age: 35 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine whether La Jolie gel is effective in the treatment of periorbital wrinkles.

Detailed description

Argireline has mechanism of action that significantly inhibited neurotransmitter release with a potency similar to that of BoNTA. Inhibition of neurotransmitter release was due to the interference of the hexapeptide with the formation and/or stability of SNARE complex. Notably, this peptide did not exhibit in vivo oral toxicity nor primary irritation at high doses. These findings demonstrate that Argireline is a anti-wrinkle peptide that emulates the action of currently used BoNTs. In vivo study, Topical Argireline 10% is applied on lateral preorbital area twice daily for 30 days. The result demonstrates a significant anti-wrinkle activity by decreased skin wrinkle 30%. These findings demonstrate a significant anti-wrinkle activity for Argireline, in agreement with its in vitro and cellular activities. Topical Argireline represents a bio-safe alternative to BoNTs in anti-wrinkle therapy.

Conditions

• Wrinkles

Interventions

Type	Name	Description
DRUG	10% Argireline	10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-09-01
• Completion: 2009-09-01
• First posted: 2011-06-27
• Last updated: 2011-06-27

Locations

1 site across 1 country: Thailand